BioStock: CLS revises strategy – increases focus on neurosurgery
Clinical Laserthermia Systems revises its strategy to increase the possibility of achieving the goal of reaching a positive cash flow in 2026. The new strategy prioritizes the neurosurgery business area, enabling cost savings of approximately SEK 65 million.– The background to the announced changes to the business is the strength of the ClearPoint Prism product offering, a strength that has become increasingly clear in the spring of 2024 through the initial market launch in the US, CLS writes.Read the full article at biostock.se : https://www.biostock.se/en/
